StockData
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. (SNOA) stock

SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3084% below fair value
$0.72−0.09 (-10.83%)

Close on Nov 20, 2026Market cap $3.46MP/E –Yield –

Sonoma Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Sonoma Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$2.66M. For fiscal 2026 it was -$4.13M. The highest annual figure on record is $893.00K in fiscal 2013.

Annual free cash flow

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$4.13M–
FY2025Mar 31, 2025-$168.00K–
FY2024Mar 31, 2024-$2.40M–
FY2023Mar 31, 2023-$6.42M–
FY2022Mar 31, 2022-$4.39M–
FY2021Mar 31, 2021-$3.56M–
FY2020Mar 31, 2020-$4.80M–
FY2019Mar 31, 2019-$11.82M–
FY2018Mar 31, 2018-$12.63M–
FY2017Mar 31, 2017-$8.56M–
FY2016Mar 31, 2016-$9.09M–
FY2015Mar 31, 2015-$6.83M–
FY2014Mar 31, 2014-$5.39M-704.0%
FY2013Mar 31, 2013$893.00K–
FY2012Mar 31, 2012-$4.37M–
FY2011Mar 31, 2011-$4.60M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026-$651.00K–
Q4 FY2026CQ1 2026Mar 31, 2026-$548.00K–
Q3 FY2026CQ4 2025Dec 31, 2025-$811.00K-244.0%
Q2 FY2026CQ3 2025Sep 30, 2025-$645.00K-296.6%
Q1 FY2026CQ2 2025Jun 30, 2025-$2.12M–
Q4 FY2025CQ1 2025Mar 31, 2025-$142.00K-183.5%
Q3 FY2025CQ4 2024Dec 31, 2024$563.00K–
Q2 FY2025CQ3 2024Sep 30, 2024$328.00K–
Q1 FY2025CQ2 2024Jun 30, 2024-$917.00K–
Q4 FY2024CQ1 2024Mar 31, 2024$170.00K–
Q3 FY2024CQ4 2023Dec 31, 2023-$1.11M–
Q2 FY2024CQ3 2023Sep 30, 2023-$1.23M–
Q1 FY2024CQ2 2023Jun 30, 2023-$232.00K–
Q4 FY2023CQ1 2023Mar 31, 2023-$2.63M–
Q3 FY2023CQ4 2022Dec 31, 2022-$379.00K–
Q2 FY2023CQ3 2022Sep 30, 2022-$1.86M–
Q1 FY2023CQ2 2022Jun 30, 2022-$1.56M–
Q4 FY2022CQ1 2022Mar 31, 2022-$1.46M–
Q3 FY2022CQ4 2021Dec 31, 2021-$327.00K-148.9%
Q2 FY2022CQ3 2021Sep 30, 2021-$1.33M–
Q1 FY2022CQ2 2021Jun 30, 2021-$1.27M–
Q4 FY2021CQ1 2021Mar 31, 2021-$1.48M–
Q3 FY2021CQ4 2020Dec 31, 2020$669.00K–
Q2 FY2021CQ3 2020Sep 30, 2020-$402.00K–
Q1 FY2021CQ2 2020Jun 30, 2020-$2.34M-422.7%
Q4 FY2020CQ1 2020Mar 31, 2020-$3.71M–
Q3 FY2020CQ4 2019Dec 31, 2019-$849.00K–
Q2 FY2020CQ3 2019Sep 30, 2019-$963.00K–
Q1 FY2020CQ2 2019Jun 30, 2019$726.00K–
Q4 FY2019CQ1 2019Mar 31, 2019-$2.76M–
Q3 FY2019CQ4 2018Dec 31, 2018-$2.39M–
Q2 FY2019CQ3 2018Sep 30, 2018-$3.58M–
Q1 FY2019CQ2 2018Jun 30, 2018-$3.09M–
Q4 FY2018CQ1 2018Mar 31, 2018-$3.06M–
Q3 FY2018CQ4 2017Dec 31, 2017-$2.17M–
Q2 FY2018CQ3 2017Sep 30, 2017-$2.60M–
Q1 FY2018CQ2 2017Jun 30, 2017-$4.79M–
Q4 FY2017CQ1 2017Mar 31, 2017-$2.89M–
Q3 FY2017CQ4 2016Dec 31, 2016-$1.60M–
Q2 FY2017CQ3 2016Sep 30, 2016-$1.67M–

More Sonoma Pharmaceuticals figures

See a number that looks wrong?